Pathogenesis, Diagnosis, and Treatment of Hepatic Encephalopathy

Journal of Clinical and Experimental Hepatology

Volumn 1, Issue 2, 2011, Pages 77-86

  Atluri, Dileep K ^a   Prakash, Ravi ^a   Mullen, Kevin D ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Hepatic encephalopathy; Pathogenesis; Treatment

Indexed keywords

AMMONIA; ANTIBIOTIC AGENT; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; BROMOCRIPTINE; DISACCHARIDE; LACTITOL; LACTULOSE; LEVODOPA; MANGANESE; METRONIDAZOLE; MINOCYCLINE; NEOMYCIN; NEUROSTEROID; NITAZOXANIDE; ORNITHINE ASPARTATE; PLACEBO; PROBIOTIC AGENT; PROKINETIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RIFAXIMIN; SEDATIVE AGENT; ZINC;

AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ASTROCYTE; BACTERIAL OVERGROWTH; BRAIN EDEMA; CELL SWELLING; CHRONIC LIVER DISEASE; CLINICAL HEPATIC ENCEPHALOPATHY SCORING SYSTEM; CLINICAL TRIAL (TOPIC); COGNITIVE DRUG RESEARCH TEST; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CRITICAL FLICKER FUSION; DEHYDRATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; INFECTION; INFLAMMATION; INHIBITORY CONTROL TEST; INTESTINE ABSORPTION; LABORATORY TEST; LIVER TRANSPLANTATION; NASOGASTRIC TUBE; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SCORING SYSTEM; ZINC DEFICIENCY;

EID: 83455181716     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(11)60126-6     Document Type: Review

References (81)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
2. Bajaj JS, Wade JB, Sanyal AJ Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50:2014-2021.
3. Bajaj JS, Cordoba J, Mullen KD, et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011, 33:739-747.
4. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009, 50:1175-1183.
5. Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28:45-49.
6. Adams RD, Foley JM The neurological disorder associated with liver disease. Proc Assoc Res Nerv Ment Dis 1953, 32:198-237.
7. Nencki M, Zaleski J On the quantitation of ammonia in animal fluids and tissues Naunyn Schmiedebergs. Arch Exp Pathol Pharmakol 1895, 36:385-396.
8. Nencki M, Pawlow J, Zaleski J On the content of ammonia in blood within organs and on formation of urea in mammals. Naunyn Schmiedebergs. Arch Exp Pathol Pharmakol 1896, 37:26-51.
9. Ehrlich M, Plum F, Duffy TE Blood and brain ammonia concentrations after portacaval anastomosis. Effects of acute ammonia loading. J Neurochem 1980, 34:1538-1542.
10. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyper-ammonemia. J Clin Invest 1979, 63:449-460.
11. Lockwood AH, Yap EW, Wong WH Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991, 11:337-341.
12. Szerb JC, Butterworth RF Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol 1992, 39:135-153.
13. Hindfelt B, Plum F, Duffy TE Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977, 59:386-396.
14. Larsen FS, Strauss G, Moller K, Hansen BA Regional cerebral blood flow autoregulation in patients with fulminant hepatic failure. Liver Transpl 2000, 6:795-800.
15. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003, 125:755-764.
16. Shawcross DL, Davies NA, Williams R, Jalan R Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004, 40:247-254.
17. Shawcross DL, Wright G, Olde Damink SW, Jalan R Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis 2007, 22:125-138.
18. Sharifi Y, Yeoman A, Austin M, et al. Defining the outcomes of severe hepatic encephalopathy in cirrhosis: inflammation is the key. Hepatology 2008, 48(Suppl):1061A.
19. Licinio J, Wong ML Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997, 100:2941-2947.
20. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010, 51:1062-1069.
21. Cauli O, Rodrigo R, Piedrafita B, Boix J, Felipo V Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 2007, 46:514-519.
22. Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011, 54:640-649.
23. Bemeur C, Desjardins P, Butterworth RF Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2010, 25:3-9.
24. Ahboucha S, Butterworth RF The neurosteroid system: implication in the pathophysiology of hepatic encephalopathy. Neurochem Int 2008, 52:575-587.
25. Atluri DK, Asgeri M, Mullen KD Reversibility of hepatic encephalopathy after liver transplantation. Metab Brain Dis 2010, 25:111-113.
26. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003, 114:188-193.
27. Prakash R, Mullen KD Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010, 7:515-525.
28. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977, 72(4 Pt 1):573-583.
29. Haussinger D, Cordoba Cardona J, Kircheis G, et al. Definition and assessment of low-grade hepatic encephalopathy. Hepatic Encephalopathy and Nitrogen Metabolism 2006, 423-432. Springer-Verlag, Netherlands. D. Haussinger, G. Kircheis, F. Schliess (Eds.).
30. Kircheis G, Fleig WE, Gortelmeyer R, Grafe S, Haussinger D Assessment of low-grade hepatic encephalopathy: a critical analysis. J Hepatol 2007, 47:642-650.
31. Hassanein TI, Hilsabeck RC, Perry W Introduction to the hepatic encephalopathy scoring algorithm (HESA). Dig Dis Sci 2008, 53:529-538.
32. Hassanein T, Blei AT, Perry W, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol 2009, 104:1392-1400.
33. Ortiz M, Cordoba J, Doval E, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007, 26:859-867.
34. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001, 34:768-773.
35. Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009, 29:629-635.
36. Iduru S, Mullen KD The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology 2008, 135:1455-1456.
37. Bajaj JS, Saeian K, Verber MD, et al. Inhibitory control test is a simple method to diagnose minimal hepatic encephalopathy and predict development of overt hepatic encephalopathy. Am J Gastroenterol 2007, 102:754-760.
38. Bajaj JS, Hafeezullah M, Franco J, et al. Inhibitory control test for the diagnosis of minimaI hepatic encephalopathy. Gastroenterology 2008, 135:1591. 600e1.
39. Mardini H, Saxby BK, Record CO Computerized psychometric testing in minimal encephalopathy and modulation by nitrogen challenge and liver transplant. Gastroenterology 2008, 135:1582-1590.
40. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002, 35:357-366.
41. Kircheis G, Bode JG, Hilger N, Kramer T, Schnitzler A, Haussinger D Diagnostic and prognostic values of critical flicker frequency determination as new diagnostic tool for objective HE evaluation in patients undergoing TIPS implantation. EurJ Gastroenterol Hepatol 2009, 21:1383-1394.
42. Bahamon-Dussan JE, Celesia GG, Grigg-Damberger MM Prognostic significance of EEG triphasic waves in patients with altered state of consciousness. J Clin Neurophysiol 1989, 6:313-319.
43. Montagnese S, Jackson C, Morgan MY Spatio-temporal decomposition of the electroencephalogram in patients with cirrhosis. J Hepatol 2007, 46:447-458.
44. Amodio P, Pellegrini A, Ubiali E, et al. The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol 2006, 117:2243-2251.
45. Cordoba J, Sanpedro F, Alonso J, Rovira A 1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain D/s 2002, 17:415-429.
46. Rovira A, Alonso J, Cordoba J MR imaging findings in hepatic encephalopathy. AJNRAm J Neuroradiol 2008, 29:1612-1621.
47. Conn H, Lieberthal M The Hepatic Coma Syndromes and Lactulose 1979, Williams and Wilkins, Baltimore.
48. van Leeuwen PA, van Berlo CL, Soeters PB New mode of action for lactulose. Lancet 1988, 1:55-56.
49. Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L Lactitol in treatment of acute hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993, 38:916-922.
50. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987, 7:639-643.
51. Als-Nielsen B, Gluud LL, Gluud C Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004, 328:1046.
52. Cordoba J, Minguez B, Vergara M Treatment of hepatic encephalopathy. Lancet 2005, 365:1384-1385. author reply 5-6.
53. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45:549-559.
54. Strauss E, Tramáte R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992, 39:542-545.
55. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003, 38:51-58.
56. Pedretti G, Calzetti C, Missale G, Fiaccadori F Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991, 23:175-178.
57. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
58. Mullen K, Prakash R Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010, 4:665-677.
59. Morgan MH, Read AE, Speller DC Treatment of hepatic encephalopathy with metronidazole. Gut 1982, 23:1-7.
60. Basu AP, Rayapudi K, Estevez J, Brown RS. A pilot study utilizing nitazoxanide for hepatic encephalopathy in Chronic Liver Disease Program and Abstracts of the 59th Annual Meeting of the American Association for the Study of Liver Diseases (Abstract). 2008(October 31-November 4):1742.
61. Holecek M Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition 2010, 26:482-490.
62. Les I, Doval E, Garcia-Martinez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol 2011, 106:1081-1088.
63. Ndraha S, Hasan I, Simadibrata M The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones 2011, 43:18-22.
64. Naylor CD, O'Rourke K, Detsky AS, Baker JP Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989, 97:1033-1042.
65. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003, CD001939.
66. Rose C, Michalak A, Pannunzio P, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998, 13:147-157.
67. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997, 25:1351-1360.
68. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998, 28:856-864.
69. Reding P, Duchateau J, Bataille C Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984, 2:493-495.
70. Marshall AW, Jakobovits AW, Morgan MY Bromocriptine-associated hyponatraemia in cirrhosis. Br Med J (Clin Res Ed) 1982, 285:1534-1535.
71. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16:138-144.
72. Als-Nielsen B, Gluud LL, Gluud C Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004, CD002798.
73. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995, 23:39-46.
74. Cordoba J, Lopez-Hellin J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004, 41:38-43.
75. Bianchi GP, Marchesini G, Fabbri A, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 1993, 233:385-392.
76. Bajaj JS Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14:3609-3615. 21.
77. Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A, Ferenci P A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int 2010, 30:574-582.
78. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-1715.
79. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011, 106:307-316.
80. Seyan AS, Hughes RD, Shawcross DL Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol 2010, 16:3347-3357.
81. Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010, 53:49-55. [Epub 2010 Jul 17.].